Cantor Fitzgerald Predicts Tourmaline Bio FY2026 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Tourmaline Bio in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($2.91) per share for the year. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last released its earnings results on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.02.

TRML has been the topic of a number of other research reports. Chardan Capital reissued a "buy" rating and issued a $70.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. Wedbush boosted their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Tourmaline Bio in a report on Monday, May 5th. Finally, Lifesci Capital assumed coverage on Tourmaline Bio in a research report on Monday, February 24th. They set an "outperform" rating and a $58.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tourmaline Bio currently has a consensus rating of "Buy" and an average price target of $49.33.

Tourmaline Bio Stock Performance

Shares of NASDAQ:TRML traded up $0.81 during trading on Wednesday, hitting $19.90. 383,726 shares of the stock were exchanged, compared to its average volume of 274,986. The company has a market capitalization of $511.13 million, a price-to-earnings ratio of -7.06 and a beta of 2.05. The company's fifty day simple moving average is $16.08 and its 200-day simple moving average is $17.25. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79.

Hedge Funds Weigh In On Tourmaline Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRML. Octagon Capital Advisors LP acquired a new position in Tourmaline Bio during the first quarter worth $13,765,000. QVT Financial LP boosted its holdings in shares of Tourmaline Bio by 107.1% during the first quarter. QVT Financial LP now owns 1,473,369 shares of the company's stock worth $22,410,000 after acquiring an additional 762,094 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in Tourmaline Bio during the 4th quarter worth $12,168,000. Pictet Asset Management Holding SA raised its stake in Tourmaline Bio by 69.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company's stock worth $8,515,000 after purchasing an additional 172,743 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Tourmaline Bio by 13,036.0% in the first quarter. Federated Hermes Inc. now owns 121,245 shares of the company's stock valued at $1,844,000 after buying an additional 120,322 shares during the period. 91.89% of the stock is owned by institutional investors and hedge funds.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.